Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells

Takanori Hayashi; Masahiro Hikichi; Jun Yukitake; Toru Wakatsuki; Eiji Nishio; Toshiaki Utsumi; Nobuhiro Harada

doi:10.18632/oncotarget.25217

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells

Takanori Hayashi _, Masahiro Hikichi, Jun Yukitake, Toru Wakatsuki, Eiji Nishio, Toshiaki Utsumi and Nobuhiro Harada

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:23451-23461. https://doi.org/10.18632/oncotarget.25217

Metrics: PDF 1326 views | HTML 2104 views | ?

Abstract

Takanori Hayashi1, Masahiro Hikichi2,*, Jun Yukitake3, Toru Wakatsuki4, Eiji Nishio5, Toshiaki Utsumi2,* and Nobuhiro Harada1

1Department of Biochemistry, School of Medicine, Fujita Health University, Aichi, Japan

2Department of Breast Surgery, School of Medicine, Fujita Health University, Aichi, Japan

3Department of Clinical Immunology, School of Health Sciences, Fujita Health University, Aichi, Japan

4Department of Health Science, School of Medicine, Fujita Health University, Aichi, Japan

5Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Aichi, Japan

*These authors contributed equally to this work

Correspondence to:

Takanori Hayashi, email: [email protected]

Keywords: everolimus; aromatase inhibitors resistance; long-term estrogen-deprived cells; PP2A; breast cancer

Received: October 17, 2017 Accepted: April 06, 2018 Published: May 04, 2018

ABSTRACT

Aromatase inhibitor (AI) resistance is a major obstacle in the treatment of estrogen receptor-positive breast cancer. Everolimus (EVE) ameliorates AI-resistant breast cancer and is therefore used in cancer treatment. However, some patients show resistance to EVE. Here, we used 30 clones of long-term estrogen-deprived (LTED) MCF-7 cells as a model of AI-resistant breast cancer. We examined changes in protein phosphatase type 2A (PP2A) and cancerous inhibitor of PP2A (CIP2A), a negative regulator of PP2A, in LTED cells treated with EVE. In LTED cells with high sensitivity to EVE, CIP2A expression decreased at low EVE concentrations; however, in LTED cells poorly sensitive to EVE, CIP2A and PP2A did not change upon exposure to EVE. Therefore, we hypothesized that there is a relation between expression of CIP2A and sensitivity to EVE. Knockdown of CIP2A increased the sensitivity to EVE in three clones poorly sensitive to EVE. Additionally, we found that treatment with FSK, which activates PP2A, increased the sensitivity of the cells to EVE. Our data point to CIP2A and PP2A as novel therapeutic targets for AI-resistant breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25217

Publication Alerts

Research Papers:

Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells

Abstract